Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current


Ligand Pharmaceuticals Revises FY23 Revenue Outlook From $124M-$128M To $124M-$126M; Est. $127.05M

Author: Benzinga Newsdesk | September 18, 2023 05:24pm

Posted In: LGND